Skip to content

Low Rectal Cancer Study (MERCURY II)

The Low Rectal Cancer Study.

Status
UNKNOWN
Phases
Unknown
Study type
Observational
Source
ClinicalTrials.gov
Registry ID
NCT02005965
Acronym
MERCURY II
Enrollment
542
Registered
2013-12-09
Start date
2007-08-13
Completion date
2021-03-11
Last updated
2018-09-18

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Adenocarcinoma, Adenocarcinoma, Mucinous, Carcinoma, Colorectal Neoplasms, Digestive System Diseases, Digestive System Neoplasms, Gastrointestinal Diseases, Gastrointestinal Neoplasms, Intestinal Diseases, Intestinal Neoplasms, Neoplasms, Neoplasms by Histologic Type, Neoplasms by Site, Neoplasms, Cystic, Mucinous, and Serous, Neoplasms, Glandular and Epithelial, Rectal Diseases

Keywords

Rectal Cancer, Low Rectal Cancer, MERCURY, Cancer, CRM, Circumferential Margin, Quality of Life, MRI, Radiology, Abdominoperineal Excision, Anterior Resection, Surgery, Pathology

Brief summary

The MERCURY Study demonstrated the accuracy, feasibility and reproducibility of Magnetic Resonance Imaging (MRI) to stage rectal cancer in a prospective, multidisciplinary, multi-centre study. However, there were differences in patient outcome, dependent upon the position of the tumour in the rectum and its height above the anal verge. Whilst the outcome was excellent for patients who underwent an anterior resection, the outcome, based upon margin involvement and quality of the specimen, was poor for patients who underwent an abdomino-perineal excision for low rectal cancer. It is proposed that accurate MRI staging pre-operatively will allow the correct patients to receive neo-adjuvant chemoradiotherapy (CRT), and also pre-warn the surgeons if the resection margins appear threatened so that the operation can be modified to take this into account. The primary aims of the Low Rectal Cancer Study (MERCURY II) are to assess the rate of CRM positivity rate in low rectal cancer and to assess the difference in global quality of life at two years post surgery in patients according to plane of surgery with or without sphincter preservation.

Detailed description

The aim of this study is to reduce the positive margin rate of 30% to around 15%. The study is an international multicentre, prospective, observational study, whereby patients with biopsy-proven low-rectal cancer (lower edge of the tumour \< 6cms from the anal verge on MRI), will be recruited from participating centres, having given informed, written consent. Data from the radiology, surgical and pathological aspects will be collected and analysed centrally at the Royal Marsden Hospital. The patient's medical records will be reviewed for five years post surgery, and the patients will also be followed up by quality of life questionnaires. This project aims to show that in low rectal cancer, improved local control and survival can be achieved through a reduction in the involved CRM rates by MRI-planned surgery and selective pre-operative therapy. It also aims to assess the ability to predict disease recurrence and to provide an assessment of disease-free survival and overall survival.

Interventions

None listed

Sponsors

Pelican Cancer Foundation
CollaboratorOTHER
Royal Marsden NHS Foundation Trust
Lead SponsorOTHER

Study design

Observational model
COHORT
Time perspective
PROSPECTIVE

Eligibility

Sex/Gender
ALL
Age
18 Years to No maximum
Healthy volunteers
No

Inclusion criteria

* Ability to give informed, written consent. * Adults age 18 or over - male or female. * Recently diagnosed with biopsy-proven, primary, low rectal cancer. * No previous therapy for rectal cancer.

Exclusion criteria

* Current pregnancy, including ectopic pregnancy. * Previous pelvic/rectal malignancy (excluding carcinoma in-situ). * Previous pelvic radiotherapy. * Previous pelvic floor surgery for faecal incontinence or prolapse.

Design outcomes

Primary

MeasureTime frame
To assess the rate of CRM positivity rate in low rectal cancer.4 years
To compare global quality of life at two years post surgery in patients according to plane of surgery with or without sphincter preservation.8 years

Secondary

MeasureTime frame
Comparison of time to local recurrence, disease-free and overall survival between patients undergoing different types of surgery.8 years
Comparison of imaging and pathology staging assessment, patient characteristics and complication rates, between different types of surgery and surgical approaches.8 years
To compare patient reported outcomes in patients according to plane of surgery with or without sphincter preservation.8 years
Investigation of potential association between length of operation with number of complications and length of post-operative ITU/HDU stay.8 years
Investigation of potential associations between imaging and pathology assessment of radial and distal margins, neo-adjuvant chemoradiotherapy, perineal complications and sphincter preservation rates.8 years
Analysis of the clinical and radiological factors influencing the decision by surgeons to carry out Anterior Resections, APE or extralevator APE.8 years

Countries

Germany, Serbia, United Kingdom

Outcome results

None listed

Source: ClinicalTrials.gov · Data processed: Feb 4, 2026